Between October 22 and November 11, 2026, full results were published or presented for 2 medicines for Sjögren's disease. Both come from phase 3 trials, the large studies that come before an approval request. Ianalumab, from Novartis, was published in the New England Journal of Medicine and is with the FDA. Dazodalibep, from Amgen, was presented at the American College of Rheumatology meeting 3 weeks later.
Both lowered a doctor-scored measure of disease activity more than a placebo did, meaning a look-alike treatment with no medicine in it. No medicine approved by the FDA was designed to treat Sjögren's disease itself, so either one could become the first. If you live with Sjögren's, or care for someone who does, the natural next question is whether these trials included people like you.
That depends on which of 2 groups a person falls into. The finished trials enrolled people whose disease was active in organs such as joints, glands, skin or blood. People whose main burden is dryness, fatigue and pain, with little organ activity, were studied in separate trials that have not reported yet.
Is There an FDA-Approved Treatment for Sjögren's Disease?
No FDA-approved medicine was designed to treat the underlying disease in Sjögren's, and the approved products mostly ease 1 symptom at a time. Only 2 medicines are approved specifically for a Sjögren's symptom. Salagen and Evoxac are both approved for the symptoms of dry mouth. Some steroid labels, such as prednisolone tablets sold as Orapred ODT, also list Sjögren's syndrome among many rheumatic conditions.
Prescription eye drops such as Restasis and Xiidra are approved for dry eye in general, and their labels do not name Sjögren's. Other medicines a rheumatologist may prescribe for organ involvement, such as rituximab, are used off-label, meaning for a purpose the label does not list. The Sjögren's Foundation's treatment guidelines describe rituximab, for example, as an option in selected situations.
The picture is different in 1 country. China's drug regulator approved telitacicept for adults with Sjögren's disease on June 8, 2026, which its developers describe as the first approval for the disease anywhere. Novartis acknowledged this in November 2026 when it wrote that no approved options exist outside China.
The name itself is changing too. An international consensus published in 2025 recommended disease in place of syndrome, and the US foundation now uses Sjögren's disease. Older labels and many trial records still say syndrome, and both names mean the same condition.
Two Kinds of Sjögren's Disease Trial, Sorted by 2 Scores
Sjögren's trials split patients by 2 scores, 1 filled in by the doctor and 1 by the patient. The doctor's score is called ESSDAI, and it rates disease activity across 12 parts of the body. A European task force set 5 or higher as the mark of moderate activity. It recommended that level as the entry point for trials of systemic disease, meaning disease that reaches beyond the tear and saliva glands.
The patient's score is called ESSPRI. It is the average of three 0 to 10 ratings for dryness, limb pain and fatigue. The same task force recommended an ESSPRI of 5 or higher as the entry point for trials aimed at symptoms.
Amgen built its program around that split, with 1 trial for each group. Most other companies ran their main trials only in the first group. Trial Friend read the entry rules of each phase 3 trial on ClinicalTrials.gov on November 16, 2026, and the table below places each drug by the group it enrolled.
Of 6 medicines in phase 3 trials for Sjögren's disease, 3 have reported results, counting telitacicept's trial in China. All 3 results come from people with a disease activity score of 5 or higher. Entry rules and status are from ClinicalTrials.gov and company releases, checked November 16, 2026.
The right-hand column matters because low doctor-scored activity is common. In a 2026 survey of US rheumatologists covering 511 patients, 44.2% had mild disease on a calculated stand-in for the doctor's score. Among 297 patients with a symptom score, 33.7% scored 5 or higher. The survey's authors work for Novartis and Adelphi Real World, the research firm whose survey program supplied the data.
Latest for Sjögren's Syndrome
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Who can joinWho can join changed for Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to… (Phase 1)ClinicalTrials.gov
- Trial statusNo longer enrolling. Study of RSLV-132 in Females With Sjögren's Disease (Phase 2, Resolve Therapeutics)ClinicalTrials.gov
Free email alert
Email me the day the FDA decides on Ianalumab
One email when the decision is public, with what it means in plain language, plus new trials and FDA news for Sjögren's Syndrome. Unsubscribe anytime.
You'll get trial alerts and disease updates for Sjögren's Syndrome, and you can turn either off anytime. We never share your email. Privacy policy
What Did Dazodalibep Do in Its Phase 3 Trial?
Dazodalibep lowered the ESSDAI score by 5.6 points at 48 weeks when given every 4 weeks, against 3.8 points on placebo. Amgen reported that gap of 1.8 points on November 11, 2026, from a trial called OASIZ-301 that randomized 648 adults. A second schedule, a larger dose every 12 weeks, lowered the score by 5.2 points, a gap of 1.4.
People entered that trial with an average score of 10.2, about twice the entry minimum. Dazodalibep is given as an infusion into a vein. It blocks a signal called CD40 ligand that immune cells use to switch each other on, and it is not an antibody.
Dryness is the result many patients will look for first, and the answer is split. Patient-rated dryness improved more than placebo with the every-4-weeks schedule, by about 1.2 points on a 0 to 10 scale. Amgen did not report a significant dryness benefit for the every-12-weeks schedule.
“the every four weeks regimen also improved patient-reported dryness”
Ghaith Noaiseh, MD, University of Kansas Medical Center, lead investigator of OASIZ-301, in an Amgen release, November 11, 2026
Some answers are still missing from what Amgen has published. Fatigue was measured in the trial, and neither the release nor the meeting abstract gives a fatigue result. Amgen said serious side effects were balanced across the 3 groups without printing the counts. The most common side effects it listed were cold symptoms, urinary tract infection, high blood pressure and reactions during the infusion.
Amgen has not said when it will ask the FDA for approval. Its second trial, OASIZ-303, enrolled people with a symptom score of 5 or higher and a doctor's score below 5. That is the trial built for the right-hand column of the table, and Amgen said in September that it expected the trial to complete in the fourth quarter of 2026.
Ianalumab Is at the FDA, With a Decision Expected in 2026
Ianalumab is the furthest along in the US, and Novartis said on November 10, 2026 that it expects an FDA decision this year. The agency granted it Breakthrough Therapy designation in January 2026, a status meant to speed the review of drugs for serious conditions. Novartis has not published the decision date, and the ianalumab decision page on Trial Friend's FDA calendar tracks it.
The evidence is a pair of trials called NEPTUNUS-1 and NEPTUNUS-2, published in the New England Journal of Medicine on October 22, 2026. A monthly injection of ianalumab lowered the ESSDAI score by 1.3 points more than placebo in the first trial and by 1.0 in the second. Both results were statistically significant, with P values of 0.0496 and 0.04.
The same paper reports no significant difference between ianalumab and placebo on either patient-rated symptom score. That finding is why the symptom question stays open for this drug. Novartis has since started a separate trial, called THALASSA, in people with a high symptom burden.
The drug is an antibody that removes B cells, a type of immune cell, and blocks a signal that helps them survive. The journal paper says serious side effects occurred at a similar rate with ianalumab and placebo, and that injection reactions were more common with the drug.
How Big Is a 1 to 2 Point Difference on the ESSDAI Scale?
A gap of 1 to 2 points over placebo is real in statistical terms, and smaller than the change the scale's authors call important for one patient. The European task force defined a meaningful improvement for an individual as a drop of at least 3 points. Those are different yardsticks, so the comparison needs care.
The 3-point figure describes what one person experiences from start to finish. In the dazodalibep trial, people on the every-4-weeks schedule dropped 5.6 points on average, well past that mark. People on placebo also dropped 3.8 points on average, which is why the difference between the groups looks small.
Placebo groups improved a good deal in both dazodalibep trials, by 3.8 points in phase 3 and 4.1 points in phase 2. Amgen and Novartis each call their results clinically meaningful, and that is the companies' own wording. How regulators weigh the gap will be clearer once the FDA rules on ianalumab.
Which Sjögren's Drug Studies Can a New US Patient Still Join?
Four phase 2 or 3 studies of medicines aimed at the disease itself are open to new US patients, by Trial Friend's count of ClinicalTrials.gov on November 16, 2026. The registry listed 49 recruiting treatment studies once every spelling of Sjögren's was searched, and 12 of those had a US site. The other 8 include phase 1 safety studies, a dry eye study, an extension closed to newcomers and an online wellness course. One cell therapy study is still listed as recruiting although its maker ended the program in October 2026.
- Telitacicept, in a phase 3 study called UPSTREAM, lists 47 US sites and requires a doctor's score of 5 or higher.
- Ianalumab, in the phase 3 THALASSA study, lists 23 US sites and enrolls people with a high dryness score.
- A Novartis medicine coded DDY391 is in a phase 2 study with 12 US sites.
- Tofacitinib, a pill approved for other diseases, is in a phase 2 safety study at the National Institutes of Health in Maryland.
One entry rule runs through nearly all of them. Each company study above asks for a positive anti-Ro antibody test, also written anti-SSA. The DDY391 study also accepts people who test negative but have a past gland biopsy showing Sjögren's. Our Sjögren's trial page lists every open study with its locations, and a rheumatologist's office can confirm the antibody result on file.
“no two people experience it in exactly the same way”
Janet E. Church, President and Chief Executive Officer, Sjögren's Foundation, quoted in an Amgen release, September 22, 2026
Nipocalimab, Deucravacitinib and the Efgartigimod Trial That Stopped
Three more medicines reached phase 3, and their stories show how uncertain this field still is. Efgartigimod, sold as Vyvgart for other diseases, was the setback. On October 8, 2026, argenx said an independent monitoring committee had concluded the trial could not meet its main goal. The company said it would discontinue the trial.
Nipocalimab, from Johnson & Johnson, works in a similar way to efgartigimod by lowering antibody levels. Its mid-stage trial, published in The Lancet in November 2025, found the higher dose lowered a version of the doctor's score more than placebo. A 655-person phase 3 trial is fully enrolled, and the registry estimates its main measurements will finish in February 2027.
Deucravacitinib, from Bristol Myers Squibb, is the only pill in the group. Its 774-person trial was due to reach its main measurement around November 18, 2026, according to the registry, and no result had been announced when this was written.
One email when the decision is public, with what it means in plain language, plus new trials and FDA news for Sjögren's Syndrome. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Dazodalibep, Ianalumab and Sjögren's Questions People Ask
Is dazodalibep approved by the FDA?
No, dazodalibep is not approved by the FDA and remains an experimental medicine. Amgen reported phase 3 results in November 2026 and has not announced a filing date. An extension study is following people from both of its main trials for up to 152 weeks.
Can my doctor prescribe dazodalibep?
No, a doctor cannot prescribe dazodalibep, because it is not approved and is available only inside studies. Its 2 main trials are closed to new patients. The one dazodalibep study still listed as recruiting is an extension that takes only people who finished those trials.
How does dazodalibep work?
Dazodalibep blocks CD40 ligand, a signal that immune cells use to switch each other on. Amgen describes it as designed to disrupt the contact between T cells, B cells and gland cells that drives the disease. A 2024 paper in Nature Medicine calls it a nonantibody fusion protein, a lab-made protein built from joined parts.
Is dazodalibep the same as ianalumab?
No, dazodalibep and ianalumab are different medicines from different companies. Amgen's dazodalibep blocks CD40 ligand and is given as an infusion into a vein. Novartis's ianalumab is an antibody against B cells that is injected under the skin once a month. No study has compared the 2 with each other.
When will the FDA decide on ianalumab?
Novartis said on November 10, 2026 that it expects the FDA's decision on ianalumab before the end of 2026. The company has not published the exact target day, often called the PDUFA date. ClinicalTrials.gov also carries a record of a managed access program for ianalumab. The record lists no locations, so whether it is open to a US patient is a question a doctor can put to Novartis.
Is there any approved medicine for Sjögren's disease?
In the US, no approved medicine was designed to treat the disease itself, and Salagen and Evoxac are approved only for its dry mouth symptoms. China approved telitacicept for adults with Sjögren's disease on June 8, 2026. Vor Bio is now testing telitacicept in a US phase 3 study with an estimated 250 participants.
What is a good ESSDAI score?
An ESSDAI score below 5 counts as low disease activity, 5 to 13 as moderate and 14 or higher as high, according to a European task force study of 790 patients. The scale runs from 0 to 123, though real scores sit far lower. A drop of 3 points or more is the task force's mark of meaningful improvement for one person.
Does dazodalibep help Sjögren's fatigue?
Amgen has not published a fatigue result from its phase 3 trial, although fatigue was one of the measures. In an earlier mid-stage trial, people with a high symptom burden improved by 1.8 points on the ESSPRI symptom score against 0.5 on placebo. That score combines dryness, pain and fatigue, so it does not isolate fatigue.
How common is Sjögren's disease?
Sjögren's disease affects 1 to 4 million people in the United States, according to the National Institute of Dental and Craniofacial Research. The institute says women are 9 times more likely to have it than men, and most people are over 50 when diagnosed.
